Metformin suppresses gastric cancer progression through calmodulin‑like protein 3 secreted from tumor‑associated fibroblasts

Chen,Guangxia; Yu,Chenxiao; Tang,Zhicheng; Liu,Shiyu; An,Fangmei; Zhu,Junjia; Wu,Qianqian; Cao,Jianping; Zhan,Qiang; Zhang,Shuyu

doi:10.3892/or.2018.6783

Metformin suppresses gastric cancer progression through calmodulin‑like protein 3 secreted from tumor‑associated fibroblasts

Authors:
- Guangxia Chen
- Chenxiao Yu
- Zhicheng Tang
- Shiyu Liu
- Fangmei An
- Junjia Zhu
- Qianqian Wu
- Jianping Cao
- Qiang Zhan
- Shuyu Zhang
View Affiliations

Affiliations: Department of Gastroenterology, The First People's Hospital of Xuzhou, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions and School of Radiation Medicine and Protection, Medical School of Soochow University, Suzhou, Jiangsu 215123, P.R. China, Department of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu 214023, P.R. China, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, Jiangsu 215123, P.R. China
Published online on: October 11, 2018 https://doi.org/10.3892/or.2018.6783
Pages: 405-414

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is one of the most common malignant tumor types worldwide, with a high morbidity and associated mortality. The interaction between gastric cancer cells and their microenvironment has a significant role in their maintenance and progression. Gastric tumor‑associated fibroblasts (TAFs) are among the major regulators of the gastric cancer microenvironment. Metformin, a classical anti‑diabetic drug, is known to prevent cancer progression. However, the effect of metformin on gastric TAFs and TAF‑associated cancer progression has remained to be elucidated. In the present study, TAFs were isolated from gastric cancer patients, pre‑treated with metformin and then co‑cultured with gastric cancer cell lines. It was demonstrated that pre‑treatment with 200 µM metformin reduced the stimulatory effect of TAFs on the proliferation of gastric cancer cells in co‑culture, suggesting that metformin impairs the tumor‑promoting role of TAFs. Using tandem mass tags‑based quantitative proteomic analysis, it was identified that metformin significantly affected the secretion of 32 proteins (14 upregulated and 18 downregulated) in the culture medium of gastric TAFs. Among these proteins, calmodulin‑like protein 3 (Calml3) was 2.88‑fold upregulated in the culture medium of gastric TAFs after metformin treatment and a further experiment using recombinant Calml3 indicated its suppressive effect on the clonogenicity of gastric cancer cells. It was concluded that metformin suppresses gastric cancer through stimulating Calml3 secretion from TAFs, which represents a novel anticancer mechanism of metformin.

View Figures

View References

1	Van Cutsem E, Sagaert X, Topal B, Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
4	Bornschein J, Selgrad M, Warnecke M, Kuester D, Wex T and Malfertheiner P: H. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci. 55:3124–3131. 2010. View Article : Google Scholar : PubMed/NCBI
5	Wang F, Meng W, Wang B and Qiao L: Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 345:196–202. 2014. View Article : Google Scholar : PubMed/NCBI
6	Jiang L, Yang KH, Guan QL, Zhao P, Chen Y and Tian JH: Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: A meta-analysis. J Surg Oncol. 107:807–814. 2013. View Article : Google Scholar : PubMed/NCBI
7	Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, et al: Treatment of gastric cancer. World J Gastroenterol. 20:1635–1649. 2014. View Article : Google Scholar : PubMed/NCBI
8	Tao L, Huang G, Song H, Chen Y and Chen L: Cancer associated fibroblasts: An essential role in the tumor microenvironment. Oncol Lett. 14:2611–2620. 2017. View Article : Google Scholar : PubMed/NCBI
9	Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H and Takeyama H: Cancer-associated fibroblasts: Their characteristics and their roles in tumor growth. Cancers. 7:2443–2458. 2015. View Article : Google Scholar : PubMed/NCBI
10	Chung HW and Lim JB: Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J Gastroenterol. 20:1667–1680. 2014. View Article : Google Scholar : PubMed/NCBI
11	Kalluri R: The biology and function of fibroblasts in cancer. Nat Rev Cancer. 16:582–598. 2016. View Article : Google Scholar : PubMed/NCBI
12	Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C and Brown RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 3:349–363. 2002. View Article : Google Scholar : PubMed/NCBI
13	Marsh T, Pietras K and McAllister SS: Fibroblasts as architects of cancer pathogenesis. Biochim Biophys Acta. 1832:1070–1078. 2013. View Article : Google Scholar : PubMed/NCBI
14	Ostman A and Augsten M: Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev. 19:67–73. 2009. View Article : Google Scholar : PubMed/NCBI
15	Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
16	Öhlund D, Elyada E and Tuveson D: Fibroblast heterogeneity in the cancer wound. J Exp Med. 211:1503–1523. 2014. View Article : Google Scholar : PubMed/NCBI
17	Yan Y, Wang LF and Wang RF: Role of cancer-associated fibroblasts in invasion and metastasis of gastric cancer. World J Gastroenterol. 21:9717–9726. 2015. View Article : Google Scholar : PubMed/NCBI
18	Pang T, Wang X, Gao J, Chen W, Shen XJ, Nie MM, Luo T, Yin K, Fang G, Wang KX, et al: Fiber-modified hexon-chimeric oncolytic adenovirus targeting cancer associated fibroblasts inhibits tumor growth in gastric carcinoma. Oncotarget. 8:76468–76478. 2017. View Article : Google Scholar : PubMed/NCBI
19	Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN and Bruchim I: In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 110:246–250. 2008. View Article : Google Scholar : PubMed/NCBI
20	Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A, Yan W, Logan SK and Li X: Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis. 34:2823–2832. 2013. View Article : Google Scholar : PubMed/NCBI
21	Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
22	Yu C, Jiao Y, Xue J, Zhang Q, Yang H, Xing L, Chen G, Wu J, Zhang S, Zhu W and Cao J: Metformin sensitizes non-small cell lung cancer cells to an epigallocatechin-3-gallate (EGCG) treatment by suppressing the Nrf2/HO-1 signaling pathway. Int J Biol Sci. 13:1560–1569. 2017. View Article : Google Scholar : PubMed/NCBI
23	Safe S, Naira V and Karki K: Metformin-induced anticancer activities: Recent insights. Metformin-induced anticancer activities: Recent insights. Biol Chem. 399:321–335. 2018. View Article : Google Scholar : PubMed/NCBI
24	Malki A and Youssef A: Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res. 19:275–285. 2011. View Article : Google Scholar : PubMed/NCBI
25	Bhalla K, Hwang BJ, Dewi RE, Twaddel W, Goloubeva OG, Wong KK, Saxena NK, Biswal S and Girnun GD: Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Philla). 5:544–552. 2012. View Article : Google Scholar
26	Chen G, Feng W, Zhang S, Bian K, Yang Y, Fang C, Chen M, Yang J and Zou X: Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling. Am J Cancer Res. 5:1423–1434. 2015.PubMed/NCBI
27	Yang B, Li M, Tang W, Liu W, Zhang S, Chen L and Xia J: Dynamic network biomarker indicates pulmonary metastasis at the tipping point of hepatocellular carcinoma. Nat Commun. 9:6782018. View Article : Google Scholar : PubMed/NCBI
28	Yang X, Xu X, Zhu J, Zhang S, Wu Y, Wu Y, Zhao K, Xing C, Cao J, Zhu H, et al: miR-31 affects colorectal cancer cells by inhibiting autophagy in cancer-associated fibroblasts. Oncotarget. 7:79617–79628. 2016. View Article : Google Scholar : PubMed/NCBI
29	Yu J, Dong X, Wang L, Ji H and Liu A: Antitumor effects of seleno-β-lactoglobulin (Se-β-Lg) against human gastric cancer MGC-803 cells. Eur J Pharmacol. 833:109–115. 2018. View Article : Google Scholar : PubMed/NCBI
30	Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD and Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59:5002–5011. 1999.PubMed/NCBI
31	Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL and Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 121:335–348. 2005. View Article : Google Scholar : PubMed/NCBI
32	Klil-Drori AJ, Azoulay L and Pollak MN: Cancer, obesity, diabetes, and antidiabetic drugs: Is the fog clearing? Nat Rev Clin Oncol. 14:85–99. 2017. View Article : Google Scholar : PubMed/NCBI
33	Vermeulen L, De Sousa E, Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, et al: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 12:468–476. 2010. View Article : Google Scholar : PubMed/NCBI
34	Borges FT, Melo SA, Özdemir BC, Kato N, Revuelta I, Miller CA, Gattone VH II, LeBleu VS and Kalluri R: TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol. 24:385–392. 2013. View Article : Google Scholar : PubMed/NCBI
35	Kahlert C and Kalluri R: Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med. 91:431–437. 2013. View Article : Google Scholar : PubMed/NCBI
36	Luga V and Wrana JL: Tumor-stroma interaction: Revealing fibroblast-secreted exosomes as potent regulators of Wnt-planar cell polarity signaling in cancer metastasis. Cancer Res. 73:6843–6847. 2013. View Article : Google Scholar : PubMed/NCBI
37	Yaswen P, Smoll A, Peehl DM, Trask DK, Sager R and Stampfer MR: Down-regulation of a calmodulin-related gene during transformation of human mammary epithelial cells. Proc Natl Acad Sci USA. 87:7360–7364. 1990. View Article : Google Scholar : PubMed/NCBI
38	Rogers MS, Foley MA, Crotty TB, Hartmann LC, Ingle JN, Roche PC and Strehler EE: Loss of immunoreactivity for human calmodulin-like protein is an early event in breast cancer development. Neoplasia. 1:220–225. 1999. View Article : Google Scholar : PubMed/NCBI
39	Brooks MD, Bennett RD, Strehler EE, Sebo TJ, Eckert SE and Carr AB: Human calmodulin-like protein (CLP) expression in oral squamous mucosa and in malignant transformation. J Prosthodont. 18:11–16. 2009. View Article : Google Scholar : PubMed/NCBI